eViralHepatitis Review
Hosted on Acast. See acast.com/privacy for more information.
- Update frequency
- every 40 days
- Average duration
- 25 minutes
- Episodes
- 45
- Years Active
- 2012 - 2022
Sofosbuvir/Velpatasvir fixed dose combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 ASTRAL-5 Study
Volume 4, Issue 8, Part 3.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. David Wyles from the University of California San Diego about his presentation: Sofosbuvir/Velpatasivr Fixed …
Resistance Analysis for Ledipasvir/Sofosbuvir containing regimens in patients infected with chronic HCV who have advanced liver disease or are post Liver Transplant (SOLAR-1 and 2 STUDIES)
Volume 4, Issue 8, Part 2.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Michael Charlton from Intermountain Medical Center about his abstract: Resistance Analyses for Ledipasvir/Sof…
High Efficacy of Sofosbuvir/Velpatasvir plus GS-9857 for 12 Weeks in Treatment-experienced Genotype 1-6 HCV-Infected Patients, Including those Previously Treated with Direct-acting Antivirals
Volume 4, Issue 8, Part 1.
Raymond T. Chung, MD from Harvard Medical School interviews Dr. Eric Lawitz from the University of Texas Health Science Center about his presentation: High Efficacy of Sofos…
Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations
Volume 4, Issue 7.
Drs Paul Martin, MD and Kalyan Ram Bhamidimarri, MD cover the important topic of Hepatitis C Treatment in the HIV Coinfected and Dialysis Populations in the format of case-study sce…
Screening for HCV and HBV Infection in the Clinic
Volume 4, Issue 5.
Arthur Y. Kim, MD covers the important topic of Screening for HCV and HBV Infection in the Clinic in the format of case-study scenarios for the clinical practice.
The post Screening …
Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015
Volume 4, Issue 3, Part 3.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Gregory Dore from the Kirby Institute, UNSW Australia about the C-EDGE CO-STAR study.
Th…
Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015
Volume 4, Issue 3, Part 2.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Graham Foster from Queen Mary University of London about the ASTRAL-3 study.
The post Ad…
Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015
Volume 4, Issue 3, Part 1.
Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Vincent Leroy from Grenoble University Hospital about the ALLY-3+ study.
The post Advanc…
The New DAAs and HCV Genotype 2/3 Patients
Volume 4, Issue 2.
David L. Wyles, MD covers the important topic of New DAAs and HCVV Genotype 2/3 Patients in the format of case-study scenarios for the clinical practice.
The post The New DAAs and HC…
INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION
Special Edition 2014, Issue 2, Part 3.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indian…
INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION
Special Edition 2014, Issue 2, Part 2.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indian…
INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO ARE COINFECTED WITH HIV, HAVE DECOMPENSATED CIRRHOSIS, OR HAVE UNDERGONE LIVER TRANSPLANTATION
Special Edition 2014, Issue 2, Part 1.
Raymond T. Chung, MD from Massachusetts General Hospital in Boston interviews Dr. Susanna Naggie from Duke University Medical Center and Dr. Paul Kwo from Indian…
INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY
Special Edition 2014, Issue 1, Part 2.
Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore discusses patients who have genotype 3 or cirrhosis, are interferon-ineligibl…
INDIVIDUALIZING THERAPY IN PATIENT SUBPOPULATIONS INFECTED WITH HCV WHO HAVE GENOTYPE 3, CIRRHOSIS, ARE INTERFERON-INELIGIBLE/INTOLERANT, OR HAVE FAILED PREVIOUS THERAPY
Special Edition 2014, Issue 1, Part 1.
Mark S. Sulkowski, MD from Johns Hopkins University School of Medicine in Baltimore interviews Dr. David Nelson from the University of Florida about patients who…
Highlights from the 2014 EASL Meeting
Volume 3, Issue 12.
Mark S. Sulkowski, MD, Professor of Medicine, Medical Director, Viral Hepatitis Center in the Divisions of Infectious Diseases and Gastroenterology/Hepatology at the Johns Hopkins …
HCV Screening and Natural History
Volume 3, Issue 10.
David Thomas, MD, Professor of Medicine, and Director of the Division of Infectious Diseases at the Johns Hopkins University School of Medicine discusses HCV screening and natural …
Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD
Volume 3, Issue 8.
Susanna Naggie, MD, Professor, Assistant Professor of Medicine, Department of Medicine – Infectious Diseases at Duke University School of Medince discusses the development of new th…
Cure of Hepatitis B: Is it Achievable?
Volume 3, Issue 6.
Dr. Fabien Zoulim, MD, PhD, Professor, head of INSERM Viral Hepatitis Laboratory at the Medical School of Lyon, Lyon 1 University, Hepatology Department, Hospices Civils de Lyon in …
The Role of Prediction Models: Best practices in Identifying Cirrhosis and HCC in Patients Infected with HBV
Volume 3, Issue 4.
Dr. Anna Suk-Fong Lok, MD, FRCP, Professor in the Department of Internal Medicine and Director of Clinical Hepatology in the Division of Gastroenterology at the University of Michig…
European Association for the Study of the Liver HCV Update
Volume 3, Issue 2.
Dr. Mark Sulkowski from The Johns Hopkins University School of Medicine discusses advancements in hepatitis C therapy presented at EASL, as well as case-study scenarios for the clin…